Talent Risk · Employers · Pharma & healthcare
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is showing signs of job cuts.
Not yet cuts: buyouts offered or a restructuring charge booked; no job cuts confirmed. Latest, on 4 November: BioCryst Pharmaceuticals reported restructuring…
How to read this page
- The label (Cutting, Signs or Quiet) comes from one published rule applied to the sources listed: the company, formal notices and named outlets. The rule
- The figures count each announcement once. Where a figure is left out, the record says why (one report only, offered not cut, same round).
- Summary says what is happening and what would change the label; Full record lists every report, linked.
What’s happening, and where
- 4 November 2026Restructuring charge in UKBioCryst Pharmaceuticals reported restructuring costs totalling $15.6 million in Q3 2026, including $6.3 million cash costs and $9.3 million non-cash costs associated with closure of Birmingham site and employee termination costs.Formal notice · SEC EDGAR
Which jobs Research and development
Next This becomes Cutting if the company, a formal notice or a second major outlet confirms cuts.
The last 12 months
No earlier cuts on our record. We have under a year of history for this employer, so there is nothing of its own to compare this with yet.
This label is our opinion, reached by applying one published rule to the sources listed. BioCryst Pharmaceuticals can correct the record at any time.
At a glance
| Label | Signs since the week to 4 Nov |
|---|---|
| Latest on the record | 4 November 2026 · Restructuring charge |
| Jobs named in cuts | Research and development |
| Where the jobs are | UK |
| Normal for them? | No earlier cuts on our record. We have under a year of history for this employer, so there is nothing of its own to compare this with yet. |
| Sources, 12 months | 1 formal notice, each linked below |
| Headquarters · sector | US · Pharma & healthcare · BCRX |
Identifiers Wikidata Q4914611 · LEI 549300Z0INP1Z5NP6J59 · SEC CIK 0000882796 · ISIN US09058V1035 · BCRX on Nasdaq · About these
What happened
Every event on the record, newest first. Open a row for the full summary and every report. How we decide
| Date | What | Jobs | Confirmed |
|---|---|---|---|
| 4 November 2026 | Restructuring chargeBioCryst Pharmaceuticals reported restructuring costs totalling $15.6 million in Q3 2026, including $6.3 million cash costs and $9.3 million non-cash costs associated with closure of Birmingham site and employee termination costs.“Research and development expenses for the quarter include one-time impairment charges associated with the closure of the Birmingham site and employee termination costs. Total restructuring costs in research and development included cash costs of $6.3 million and non-cash costs of $9.3 million.” The source
| — | Formal notice |
In their own words
“Research and development expenses for the quarter include one-time impairment charges associated with the closure of the Birmingham site and employee termination costs. Total restructuring costs in research and development included cash costs of $6.3 million and non-cash costs of $9.3 million.”
In context
How the label has changed · 26 weeks
| 4 Nov | Quiet → Signs · Not yet cuts: buyouts offered or a restructuring charge booked; no job cuts confirmed |
|---|
Peers in pharma & healthcare
- GSK2.7%
- Novartis1.1%
- Johnson & Johnson<0.1%
- BioCryst PharmaceuticalsNone
Job cuts in 12 months as a share of each employer’s workforce. BioCryst Pharmaceuticals’s workforce is not on our record, so it is shown by jobs, unranked.
Rules coming that touch pharma & healthcare
US · Made or passedTakes effect 4 January 2027
Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure
Pharmacy benefit managers must disclose compensation details to health plan fiduciaries, affecting healthcare employer costs.
Our reading Pharmacy benefit managers and affiliated brokers and consultants must disclose their compensation details to large self-insured employer health plans, which could affect how these service providers structure their fees and roles. This transparency requirement is unlikely to directly shift jobs between sectors, but could reduce demand for certain pharmacy benefit management roles if employers respond by renegotiating contracts or bringing services in-house. The rule applies to service providers working with large self-insured group health plans, not smaller employers or insurance carriers.
Relevant through its sector and market, not a finding about BioCryst Pharmaceuticals. Official sources.
Right of reply
BioCryst Pharmaceuticals can reply or correct this record at any time.
This label is our opinion, reached by applying one published rule to the sources listed.